Sendai Isawa Family Katsuyama Sake Brewery: SAMURAI SAKE: Reviving a 300-Year-Old Recipe
16.1.2025 06:00:00 CET | Business Wire | Press release
“RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cru” New Release
Sendai Isawa Family Katsuyama Sake Brewery Co., Ltd.:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250109261916/en/
Presented in a handcrafted Sendai Tansu (Photo: Business Wire)
A Legacy of Supporting Sendai's Samurai Warlord, Date Masamune
Sendai Isawa Family Katsuyama Sake Brewery Co., Ltd., which has a history of over 330 years as the official sake brewer for the Sendai Domain founded by the feudal lord Date Masamune, released RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cruon December, 2024.
This sake, crafted by unraveling a recipe from 300 years ago, achieves a quality that extracts "twice the umami components of rice" through Katsuyama Brewery's unique centrifugal pressing method. Then, through 12 years of ice aging at minus 5 degrees Celsius, this sake has reached a level of maturity brought about by time.
Shaped by Date Masamune's legacy as a samurai leader and cultural patron, Sendai embodies his vision through international exchange and crafts like Sendai Tansu. Katsuyama Sake Brewery, the Date family's official brewery for over 300 years, honors this heritage while crafting globally renowned sake.
Winner of Prestigious Sake Competitions Worldwide!
Katsuyama Sake Brewery has earned numerous accolades. Junmai Ginjo "Ken" topped the SAKE COMPETITION in 2015 and 2016 and was Champion Sake at the 2019 London IWC. That year, Junmai Daiginjo "Den" won the President Sake title at France's KURA MASTER. Flagship Junmai Daiginjo "Akatsuki" scored 95 points from Robert Parker's Wine Advocate in 2016, ranked first among 800 new sakes, and placed second in the 2024 SAKE COMPETITION Super Premium category.
An Uniquely Exceptional Sake, Reviving a 300-Year-Old Recipe
The theme "Ryoan" honors Heizaemon Isawa, the sixth-generation owner of Katsuyama Sake Brewery, who played a key role in Sendai's growth. His restoration of Zuihō-ji, the Date family's ancestral temple, preserved traditional culture. Inspired by the legacies of Masamune and Heizaemon, RYOAN LEGEND 2012 Junmai Daiginjo embodies Sendai's history, Samurai’s pride, and innovation.
Inspired by Edo-period (1603-1868) sake recipes, this sake combines tradition and innovation. Using historical methods, it amplifies umami, unlocking rice's potential for a rich, smooth finish. Made from 2012 Yamada Nishiki Special A rice, grown near Mount Izumigatake with silica-rich water, it reflects Katsuyama’s unique terroir. With centrifugal extraction and 12 years of cold aging, it achieves a perfect balance of depth, umami, and crispness.
Presented in a handcrafted Sendai Tansu, this limited release of 50 sets offers an unparalleled experience of premium rice’s sake.
RYOAN LEGEND 2012 Junmai Daiginjo-DOUBLE UMAMI FINISH - Umami Grand Cru |
Ingredients: Rice (domestic), Rice Koji (domestic rice) |
Polishing Ratio: 35% |
Rice Variety: 100% Yamada Nishiki |
Alcohol Content: 16% |
Volume: 720ml |
Storage: Refrigerated (room temperature during transport is acceptable) |
Brewmaster: Mitsuaki Goto |
Recommended Serving Temperature: 8–14°C |
Price: ¥1,000,000 (excluding tax) |
Sales: Limited to 50 bottles |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109261916/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom